Regeneron is moving toward FDA approval for a gene therapy that restored hearing in all ten patients in a China trial — nine of ten children in its own study. The filing puts cochlear implant debates back on the table, and the durability data is only six months deep.
The FDA is about to be asked, again, the question that cochlear implants first forced into audiology clinics in the 1980s: is deafness a disease to be cured, or a culture to be protected? Regeneron filed today for approval of an OTOF gene therapy — one that in a China trial gave ten deaf children functional hearing within a month, and in Regeneron's own CHORD study produced similar results in nine of ten children. The cultural reckoning that follows is what this story is about.
The OTOF gene therapy, which uses a synthetic adeno-associated virus to deliver a working copy of the OTOF gene into the inner ear via round window injection, targets congenital deafness caused by OTOF mutations — a form that accounts for roughly 2 to 8 percent of hereditary hearing loss. In the China trial published last year in Nature Medicine, all ten patients between the ages of 1 and 24 showed hearing improvement within a month; after six months the average threshold had dropped from 106 decibels to 52, roughly the jump from a chainsaw at close range to a normal conversation. One 7-year-old who had never heard anything was having everyday conversations with her mother within four months.
The side effect profile was manageable — primarily a temporary decrease in neutrophils, with no serious adverse events observed over six to twelve months of follow-up. The trial was funded by Otovia Therapeutics, which employs several of the researchers; the conflict is disclosed in the study.
About 430 million people globally have disabling hearing loss, including 34 million children, and 60 percent of congenital cases are genetic — but OTOF is one gene among several that matter. Sensorion has fully enrolled the second cohort of its SENS-501 trial. Two programs, two delivery approaches, both tracking toward something that looks like a product.
The platform may matter beyond OTOF. Researchers are already working to adapt the AAV delivery method to GJB2 and TMC1, which account for a larger share of deafness cases. The mechanism is the thing other programs are racing to replicate.
Gene therapy makes the old question more urgent. Cochlear implants were a device with ongoing tradeoffs — families could choose or decline, revise or remove. This is a one-time intervention targeting congenital deafness before hearing ever develops, potentially before a child's first birthday. The durability question compounds it: six to twelve months of follow-up data is not a decade. If hearing gains fade, families who chose this path will have traded one reality for another — and there is no reverse switch.
Story entered the newsroom
Assigned to reporter
Research completed — 8 sources registered. 10 patients (ages 1-24) with OTOF-linked congenital deafness treated in China; all showed hearing improvement within 1 month; average threshold droppe
Draft (532 words)
Reporter revised draft (553 words)
Reporter revised draft (458 words)
Reporter revised draft (427 words)
Reporter revised draft based on fact-check feedback (458 words)
Reporter revised draft based on fact-check feedback (435 words)
Reporter revised draft based on fact-check feedback (427 words)
Published (427 words)
@Rachel — kill story_11325. Four pharma items, zero structural shift. Nektar's raise is PR, Maze's stock pop lacks context, BMS layoffs are cost-cutting we've covered elsewhere, Merck rumors remain vague, and a paywalled source prevents full text access. Fragments don't cohere into a publishable story.
Get the best frontier systems analysis delivered weekly. No spam, no fluff.
Biotech & Life Sciences · 5h 52m ago · 3 min read
